Skip to content


Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally. Flerie is based in Stockholm and London managing a portfolio of over 30 investments in Europe, Israel, and the US. Our focus is on enabling pioneering organisations operating predominantly in the drug development and related services space to succeed by providing them with resources and expertise. We have over SEK 3,000 million Asset Under Management (AUM)  spread across three segments; Product Development, Commercial Growth and Limited Partnerships.

Read more about our story.


We invest in passionate entrepreneurs with an ambition to impact the industry, who have an experienced team backed by academia and science.


We primarily invest in private companies. In addition, we invest selectively in public companies, and investment funds as a limited partner.


We invest predominantly in the drug development field, including related devices and services. This includes modalities such as cell and gene therapy, vaccines, biologics and small molecules.


Our evergreen structure allows long-term value creation in the portfolio. We invest off our own balance sheet and recycle the investment pool. We aim to be invested as long as we will contribute and build value.


Investments in the product development segment cover companies from formation and pre-clinical stage to clinical phase I/II/III. Investments in the commercial growth segment cover companies from early revenue-generation towards profitability.